[go: up one dir, main page]

AR132838A1 - PRMT5 INHIBITORS AND THEIR USES - Google Patents

PRMT5 INHIBITORS AND THEIR USES

Info

Publication number
AR132838A1
AR132838A1 ARP240101396A ARP240101396A AR132838A1 AR 132838 A1 AR132838 A1 AR 132838A1 AR P240101396 A ARP240101396 A AR P240101396A AR P240101396 A ARP240101396 A AR P240101396A AR 132838 A1 AR132838 A1 AR 132838A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
prmt5 inhibitors
stereoisomer
compound
acceptable salt
Prior art date
Application number
ARP240101396A
Other languages
Spanish (es)
Inventor
Xiao Ding
Xiaoyu Ding
Hongfu Lu
Feng Ren
Meng Zhang
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of AR132838A1 publication Critical patent/AR132838A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula (1), o una sal o estereoisómero farmacéuticamente aceptable del mismo. Una composición farmacéutica caracterizada porque comprende un compuesto de cualquiera de las reivindicaciones 1 - 35, o una sal o estereoisómero farmacéuticamente aceptable del mismo, y un portador o excipiente farmacéuticamente aceptable.A compound of formula (1), or a pharmaceutically acceptable salt or stereoisomer thereof. A pharmaceutical composition characterized in that it comprises a compound of any one of claims 1-35, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.

ARP240101396A 2023-06-02 2024-05-31 PRMT5 INHIBITORS AND THEIR USES AR132838A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2023098094 2023-06-02
CN2023133986 2023-11-24
CN2024071562 2024-01-10
CN2024091509 2024-05-07

Publications (1)

Publication Number Publication Date
AR132838A1 true AR132838A1 (en) 2025-08-06

Family

ID=93656693

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101396A AR132838A1 (en) 2023-06-02 2024-05-31 PRMT5 INHIBITORS AND THEIR USES

Country Status (4)

Country Link
CN (1) CN121285551A (en)
AR (1) AR132838A1 (en)
TW (1) TW202513565A (en)
WO (1) WO2024245412A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250175331A (en) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 PRMT5 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302820A (en) * 2020-11-24 2023-07-01 Amgen Inc Tricyclic carboxamide derivatives as prmt5 inhibitors
EP4288435A1 (en) * 2021-02-04 2023-12-13 Amgen Inc. Tricyclic-amido-bicyclic prmt5 inhibitors
CA3257612A1 (en) * 2022-07-15 2025-03-19 Abbisko Therapeutics Co., Ltd. Prmt5 inhibitor, preparation method therefor, and pharmaceutical use thereof
CA3257212A1 (en) * 2022-08-03 2025-03-19 Abbisko Therapeutics Co., Ltd. Nitrogen-containing fused three ring prmt5 inhibitor, and preparation method therefor and pharmaceutical use thereof

Also Published As

Publication number Publication date
WO2024245412A1 (en) 2024-12-05
TW202513565A (en) 2025-04-01
CN121285551A (en) 2026-01-06

Similar Documents

Publication Publication Date Title
AR133988A1 (en) RAS-PI3K INHIBITORS AND THEIR USES
AR132007A1 (en) COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K
CO2022012975A2 (en) Biaryl derivatives as inhibitors of yap/taz-tead protein-protein interaction
AR128931A1 (en) COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF
AR131639A1 (en) KIF18A INHIBITORS AND THEIR USES
AR127501A1 (en) PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF
AR128932A1 (en) BCL-XL INHIBITORS
AR134265A1 (en) HETEROCYCLES AND THEIR USES
UY40235A (en) HETEROARYL COMPOUNDS FOR PAIN TREATMENT
MX2022001743A (en) SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUOR-1,2,3,4-TETRAHI DRONAFTALEN-2-IL)AMINO)-N-(1-(2-METHYL) -1-(NEOPENTYLAMINO)PROPAN-2- IL)-1H-IMIDAZOLE-4-IL)PENTANAMIDE AND USES THEREOF.
AR132838A1 (en) PRMT5 INHIBITORS AND THEIR USES
AR130602A1 (en) TEAD INHIBITORS AND METHODS OF USE THEREOF
CL2025000529A1 (en) Dioxoisoquinolinone derivatives, inhibitors of Ezh1 and/or Ezh2; used to treat cancer.
UY39727A (en) BICYCLIC HETEROAROMATIC INHIBITORS OF KALLIKREIN-RELATED PEPTIDASE 5 (KLK5)
CO2026000093A2 (en) Pharmaceutical compositions for nek7 kinase inhibitors
AR132983A1 (en) KEAP1 INHIBITORS AND THEIR USES
CL2022002490A1 (en) Biaryl derivatives as inhibitors of yap/taz-tead protein-protein interaction
AR132166A1 (en) NLRP3 INFLAMMASOME INHIBITORS AND THEIR USES
AR134204A1 (en) NEW COMPOUNDS AS SODIUM CHANNEL MODULATORS AND THEIR USES
AR132764A1 (en) TYK2 INHIBITORS AND THEIR USES
AR130747A1 (en) NOVEL TRICYCLE-DERIVED COMPOUNDS AND THEIR USES
AR130979A1 (en) HETEROCYL COMPOUNDS AND THEIR USES
AR129588A1 (en) KRAS INHIBITORS
AR133115A1 (en) KRAS INHIBITORS
AR132055A1 (en) Dual CDK8/19 inhibitors and methods of using them